trial

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

NCTId NCT02021201
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 1 (actual)
Sponsored by Birte Glenthoj
Primary completion 2013-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
1 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2008-07
Primary completion
2013-07
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
RisperidoneSertindole

Sponsors

Birte GlenthojLead Sponsor
Icahn School of Medicine at Mount SinaiCollaborator

Investigators

4
Birte Y Glenthoj, professorStudy Director
Bob Oranje, PHDPrincipal Investigator
Birgitte Fagerlund, PhDPrincipal Investigator
Rita S Godske, MDPrincipal Investigator

Sites

1 total
Glostrup Municipality, Denmark

Facts & assertions

4 sourced
Enrollment
1
Phase
PHASE4
Primary Completion Date
2013-07
Status
TERMINATED
relationships
The graph out of here
drug
Risperidone
drug
Sertindole
drug
lead_sponsor
Birte Glenthoj
company
collaborator
Icahn School of Medicine at Mount Sinai
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Birte Y Glenthoj, professor
person
Bob Oranje, PHD
person
Birgitte Fagerlund, PhD
person
Rita S Godske, MD
person